BPGbio
BPGbio is a clinical-stage biopharmaceutical organization focused on diseases driven by mitochondrial dysfunction. The company advances a pipeline anchored by a lead clinical program and combines AI-driven discovery platforms, multi-omic biomarker development, translational sciences, and clinical development capabilities to progress programs across oncology, mitochondrial and rare diseases. The organization also maintains a large global patent portfolio and pursues external partnerships and licensing.
Industries
Nr. of Employees
medium (51-250)
Patents
Methods for the treatment of cancer using coenzyme Q10 combination therapies
US-12691081-B2
View DetailsCoenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
US-12616666-B2
View Details
Methods for the treatment of cancer using coenzyme Q10 combination therapies
US-12691081-B2
View DetailsCoenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
US-12616666-B2
View DetailsProducts
BPM31510 (clinical-stage therapeutic program)
Clinical-stage therapeutic program focused on indications driven by mitochondrial dysfunction, with active Phase 2 trials in oncology and programs in mitochondrial and rare diseases.
BPM31510 (clinical-stage therapeutic program)
Clinical-stage therapeutic program focused on indications driven by mitochondrial dysfunction, with active Phase 2 trials in oncology and programs in mitochondrial and rare diseases.
Services
Collaborative arrangements for licensing assets, research partnerships and strategic alliances to advance development programs.
Application of integrated AI/ML analytics and causally-informed models to identify targets, biomarkers, and guide translational research.
Collaborative arrangements for licensing assets, research partnerships and strategic alliances to advance development programs.
Application of integrated AI/ML analytics and causally-informed models to identify targets, biomarkers, and guide translational research.
Expertise Areas
- Clinical trial management
- Translational medicine and biomarker development
- AI/ML-driven drug discovery
- Preclinical development and DMPK
Key Technologies
- Bayesian causal AI and machine learning
- Integrated multi-omics analytics
- Mass spectrometry-based omics
- Cloud-based analytics and data integration
News & Updates
Corporate appointment of Jason Krause to a senior legal and corporate role.
Preliminary data from ongoing Phase 2 study of lead clinical program in newly diagnosed glioblastoma
Announcement reporting encouraging preliminary clinical data from an ongoing Phase 2 study in newly diagnosed glioblastoma.
Presentation of clinical and translational data supporting the therapeutic program in primary CoQ10 deficiency at a scientific meeting.
Maintains a global patent portfolio with over 400 US and international patents and applications.
Corporate appointment of Jason Krause to a senior legal and corporate role.
Preliminary data from ongoing Phase 2 study of lead clinical program in newly diagnosed glioblastoma
Announcement reporting encouraging preliminary clinical data from an ongoing Phase 2 study in newly diagnosed glioblastoma.
Presentation of clinical and translational data supporting the therapeutic program in primary CoQ10 deficiency at a scientific meeting.
Maintains a global patent portfolio with over 400 US and international patents and applications.